title: Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.
abstract: The safety and immunogenicity of REMUNE, an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV, the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE to treat HIV-1 infection.
authors.affiliation: Department of Pathobiology, Mahidol University, Bangkok, Thailand.
authors.forename: A
authors.initials: A
authors.lastname: Limsuwan
authors.forename: V
authors.initials: V
authors.lastname: Churdboonchart
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: W
authors.initials: W
authors.lastname: Sirawaraporn
authors.forename: R
authors.initials: R
authors.lastname: Sutthent
authors.forename: B
authors.initials: B
authors.lastname: Smutharaks
authors.forename: D
authors.initials: D
authors.lastname: Glidden
authors.forename: R
authors.initials: R
authors.lastname: Trauger
authors.forename: G
authors.initials: G
authors.lastname: Theofan
authors.forename: D
authors.initials: D
authors.lastname: Carlo
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D000328:Adult; D000595:Amino Acid Sequence; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization; D008297:Male; D008969:Molecular Sequence Data; D012367:RNA, Viral / Q000097:blood; D013785:Thailand
chemical_list: D016915:AIDS Vaccines; D012367:RNA, Viral; C105086:remune